• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention relates to a novel process for the halogenation in 2-position of ergot alkaloids. The process is characterized by that as a halogenating agent a system consisting of dimethylsulfoxide, a trialkylhalosilane or triarylhalosilane and optionally a hydrogen halide is used.
    公开号:SU1528320A3
    申请号:SU874202820
    申请日:1987-06-26
    公开日:1989-12-07
    发明作者:Медьери Габор；Кеве Тибор；Ковач Лайош；Штефко Бела；Богш Эрик；Кашшаи Анна；Тришлер Ференц；Сепеши Габор；Газдаг Мария
    申请人:Рихтер Гедеон Ведьесети Дьяр Рт (Инопредприятие)；
    IPC主号:
    专利说明:

    This invention relates to an improved method for producing 2-brom ergocriptine of the formula
    SNS SNZ
     /
    snon
    .CONH
    .N-ch.
    ABOUT
    H Ng
    sn
    SNO CH-:
    or its acid addition salts of a known derivative of ergo talcaloids, which exhibits neutropeptic and antihypoxic properties.
    The aim of the invention is to develop a selective bromination method, with which it is possible to brominate more preferably a zirconium skeleton in the 2-position, in particular in ergocryptine, and an increase in the yield of the target product.
    According to the proposed method, the bromination proceeds at room temperature for a very short time.
    CM
    31
    meni f5-20 min). The system chosen as the booking agent provides for mild reaction conditions, i.e. Also, when used in industry, no special devices are needed. The method is less sensitive to the water content with dimethylsulfoxide, which is extremely important for the industrial process.
    Highly selective and proceeding without side reactions, the halogenation reaction gives a yield of 90-95%, i.e. the treatment of the reaction mixture and the purification of the product are simple; chromatographic purification is not necessary in the case of known methods.
    If a raw mixture of bases or a salt thereof is used as the starting material, the resulting mixture of 2-halogenated alkaloids is dissolved in the base water. The resulting 2-halogenated alkaloid is then separated from the accompanying alkaloids by chromatography.


    Example 1 2-Bromo-oxygrissine.
    1.3 ml of trimethylbromosilane is added to 40 ml of anhydrous dimethylsulfoxide (based on the amount of the substance to be reserved, this is a sevenfold equivalent amount). The mixture is stirred at room temperature for 15 minutes and then added to a solution of 1 g of 0.001739 mol) oi-ergocriptine. The mixture was stirred at room temperature for 10 minutes, then poured into 200 ml of ice-cold water, alkalized with ammonia to pH 8-9, then extracted three times with 50 ml of dichloromethane. The combined extracts are washed three times with 30 ml of 10% sodium chloride solution, then dried over sodium sulfate, filtered and concentrated to a volume of 10 ml in vacuo. The residue is applied to an alumina column, which is pre-moistened with a 1: 1 mixture of dichloromethane and ethyl acetate. Get 50 ml of the product.
    This fraction is triturated to dryness, the residue is dissolved in 10 ml of dichloromethane, the solution is diluted with 30 ml of diisopropyl ether and then concentrated to half its volume at atmospheric pressure. The isolated white crystals are filtered, washed and then dried.
    The output of 1.06 g (0,001617 mol), 93%, so pl. 2184. -195 ° C (with 1, dichloromethane).
    Example 2. 2-Bromo- «| ergocryptin-methanesulfonate.
    0
    five
    0
    five
    0
    five
    0
    1.06 g (0.001617 mol) of 2-6poM-od-ergocryptine base is dissolved in 20 ml of dichloromethane and 30 ml of methylstil ketone is added to the solution. After adding an equivalent amount (0.152 g of methanesulfonic acid, methanesulfonate precipitates. The crystals are filtered off, washed with 5 ml of methyl ethyl ketone and then dried.
    Yield 1.1 g (0.001466 mol), 90.6%. M.p. 192-19b with.
    MD ° + 95 ° C (s 1, SI CL: CHOK 1: 1).
    Example 3. 2-Bromo- (x gregkriptina.
    1 g of oL-ergocriptine phosphate, analogously to Example 1, is brominated with 2.0 ml of trimethylbromosilane and the 2-bromo-o-ergocriptine base is separated.
    Yield 0.9 g (O 001359 mol), 91.5%, so pl. 218 ° C. -195 ° С (с 1, dichloromethane).
    Example 4. 2-Bromo-o (; - ergocryptine.
    9.1 ml of trimethyl bromosilane is added to 1000 ml of anhydrous dimethyl sulfoxide. The mixture is stirred at room temperature for 15 minutes. After this, 10 g of a base mixture of o-ergocriptine and ergozin containing,%: ob-ergocryptin 64, 2; ergozin 28.4; ui-ergocryptinine 2.78; ergozinin 1.96. The reaction mixture is stirred for 20 minutes, then poured into 5 l of ice water and basified with ammonia to pH 8-9. The mixture is extracted three times with 500 ml ds dichloromethane. The combined organic phases are shaken three times with 200 ml each with 10% sodium chloride solution, dried over sodium sulfate, filtered and evaporated in vacuo. The residue after evaporation is chromatographed on silica gel using ethyl acetate.
    The yield of 2-bromo-y, -ergocr1Ttina based on the initial mixture of bases 6, (0.00967 mol), 87%, so pl. 218 ° C; 2-bromo-ergozina 2.9 g (0.0046 mol), 89%, mp. 183-185 ° C.
    Example 5. 2-Bromo-x1-ergocryptine.
    0
    or its acid additive salts from " 6-ergocriptine by bromination thereof, characterized in that, in order to increase the selectivity of the process and increase the yield of the target product, b-bromination is subjected to ob-ergocriptine or a mixture of bases containing, along with od-ergocriptine ergotalkaloids, like ob-ergocryptin, ergozin, ergozinin or their
    Shz Shz
    h / "
    SI
    , CONH .N-CH.
    acid addition salts, and the process is carried out using a system consisting of dimethyl sulfoxide and trimetibbromosilan at room temperature and the resulting desired product is separated, if necessary, by chromatography from accompanying 2-bromo-ergotalkaloids or, if necessary, translated in acid additive salt.
    权利要求:
    Claims (1)
    [1]
    Claim
    10 .
    A method of producing 2-bromo-s (.- ergocriptine of the formula cn 3 cn or its acid addition salts from "ύ-ergocriptine by bromination, characterized in that, in order to increase the selectivity of the process and increase the yield of the target product, ο -ergocriptine or a mixture of bases containing, along with ob-ergocriptine, ergotalkaloids such as οό -ergocriptine, ergosin, ergosinin or their
    25 acid addition salts, and the process is carried out using a system consisting of dimethyl sulfoxvd and trip ipbromeylan at room temperature and the obtained target product
    30, if necessary, are chromatographically separated from the concomitant 2-bromo-ergotalkaloids or, if necessary, converted to an acid addition salt.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1528320A3|1989-12-07|Method of obtaining 2-brom-alpha-ergocryptine or acid-additive salts thereof
    Sundberg et al.1976|Lithiation of methoxyindoles
    SU421187A3|1974-03-25|METHOD OF OBTAINING 2- | -6,7- BENZOMORPHANES
    JPH06179677A|1994-06-28|Production of physostigmine carbamate derivative from eseretol
    US6197998B1|2001-03-06|Process for producing N-glycyltyrosine and its crystal structure
    KR20000052891A|2000-08-25|Method of preparation of physostigmine carbamate derivatives from eseretholes
    CS205003B2|1981-04-30|Process for preparing vincamine and similar indole alkaloids
    WO2015114595A1|2015-08-06|A process for preparation of |-1,6-diaza-bicyclo [3.2.1]octane-2-carbonitrile-7-oxo-6-|-mono sodium salt
    US4697017A|1987-09-29|Process for the preparation of 2-bromo-α-ergocryptine
    CS261250B2|1989-01-12|Method of 1-methylaminoquinolinecarboxyl acid's and its derivatives production
    JPH07121931B2|1995-12-25|Benzo [b] furan derivative
    Anastasia et al.2001|Simple and selective one-pot replacement of the N-methyl group of tertiary amines by quaternization and demethylation with sodium sulfide or potassium thioacetate: an application to the synthesis of pergolide
    DE2938313C2|1988-07-07|
    SU436493A3|1974-07-15|
    JPH0741495A|1995-02-10|14alpha-hydroxy-4-androstene-3,6,17-trione hydrate crystal and its production
    DE1695682A1|1971-04-08|New heterocyclic compounds and processes for their preparation
    Poliakoff et al.1973|Synthetic trypanocides. 3. Structure-activity relations
    SU442601A1|1974-09-05|Method for producing azepine derivatives
    RU2002744C1|1993-11-15|Method of synthesis of 1-substituted 6-fluoro-4-oxo-7-|-1,4- -dihydroquinoline-3-carboxylic acid
    HU176218B|1981-01-28|Process for preparing apovincamine from vincamine or epivincamine
    SU1468902A1|1989-03-30|Method of producing pyrano/3,4-b/indols
    Yajima et al.1977|Synthesis of 2-and 4-Bromoquinolines with a New Brominating Reagent, PBr3-DMF
    KR940005017B1|1994-06-09|Process and production of pyrimidine derivatives
    RU2002748C1|1993-11-15|Method of synthesis of 2,3,4,5-tetrahydro-5-methyl-2-[5- methyl-1h-imidazole- -4-yl) methyl]-1h-pyrido |-indole-1-one or ots salt
    US3364228A|1968-01-16|3-hydroxymethyl-4-|-hexahydro-1h-azepines and method of preparation
    同族专利:
    公开号 | 公开日
    EP0251732A3|1989-05-10|
    PL266477A1|1988-07-21|
    YU119987A|1988-06-30|
    AR243194A1|1993-07-30|
    AU597673B2|1990-06-07|
    UA5571A1|1994-12-28|
    CS479187A2|1988-09-16|
    CA1301163C|1992-05-19|
    US4816587A|1989-03-28|
    DD264430A5|1989-02-01|
    AT88705T|1993-05-15|
    JPS6314783A|1988-01-21|
    EP0251732A2|1988-01-07|
    HUT44541A|1988-03-28|
    BG48811A3|1991-05-15|
    DK328687A|1987-12-28|
    DE3785613T2|1993-08-12|
    JPH085879B2|1996-01-24|
    YU46557B|1993-11-16|
    FI89048C|1993-08-10|
    EP0251732B1|1993-04-28|
    FI872852A0|1987-06-26|
    DE3785613D1|1993-06-03|
    CS264295B2|1989-06-13|
    HU196394B|1988-11-28|
    PL151562B1|1990-09-28|
    AU7476387A|1988-01-07|
    ES2054672T3|1994-08-16|
    FI89048B|1993-04-30|
    FI872852A|1987-12-28|
    DK328687D0|1987-06-26|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3901894A|1974-06-06|1975-08-26|Lilly Co Eli|8-thiomethylergolines|
    US3992422A|1975-08-14|1976-11-16|Schering Corporation|Process for the preparation of 21-halogeno-21-desoxy-17α-acyloxy-20-keto-pregnenes|
    US4098790A|1976-09-15|1978-07-04|Eli Lilly And Company|Ergoline chlorination process|
    YU216177A|1977-09-09|1984-02-29|Rudolf Rucman|Process for preparing 2-bromo ergosine|
    US4166182A|1978-02-08|1979-08-28|Eli Lilly And Company|6-n-propyl-8-methoxymethyl or methylmercaptomethylergolines and related compounds|
    YU39849B|1978-09-26|1985-04-30|Lek Tovarna Farmacevtskih|Process for preparing 2-bromo-ergolene and 2-bromo-ergoline compounds|
    HU193317B|1985-06-12|1987-09-28|Richter Gedeon Vegyeszet|Process for producing 2-bromo-alpha-ergochristin|
    HU193782B|1985-06-21|1987-11-30|Richter Gedeon Vegyeszet|Process for producing 2-halogeno-nicergoline derivatives and acid additional salts thereof|
    HU193780B|1985-06-21|1987-11-30|Richter Gedeon Vegyeszet|Process for producing 2-halogeno-6-methyl-ergol-9-ene derivatives and acid additional salts thereof|
    HU196598B|1986-04-25|1988-12-28|Richter Gedeon Vegyeszet|Process for producing 1- and/or 8-substituted 2-halogenated ergoline derivatives and pharmaceutics comprising such compounds|HU196598B|1986-04-25|1988-12-28|Richter Gedeon Vegyeszet|Process for producing 1- and/or 8-substituted 2-halogenated ergoline derivatives and pharmaceutics comprising such compounds|
    DE4033496A1|1990-10-20|1992-04-23|Sandoz Ag|NEW ERGOL DERIVATIVES, THEIR PRODUCTION AND USE|
    AU688751B2|1993-01-12|1998-03-19|Biogen Idec Ma Inc.|Recombinant anti-VLA4 antibody molecules|
    US20030157642A1|1997-07-15|2003-08-21|Caldwell Robert M.|Increasing production of proteins in gram-positive microorganisms|
    US6723550B1|1997-07-15|2004-04-20|Genencor International, Inc.|Proteases from gram-positive organisms|
    US6521421B1|1997-07-16|2003-02-18|Genencor International, Inc.|Expression vectors encoding Bacillus subtilis disulfide bond isomerase and methods of secreting proteins in gram-positive microorganisms using the same|
    US6521440B1|1997-09-15|2003-02-18|Genencor International, Inc.|Proteases from gram-positive organisms|
    US6316241B1|1997-11-20|2001-11-13|Genencor International, Inc.|Alpha/beta hydrolase-fold enzymes|
    FR2786099B1|1998-11-24|2000-12-29|Aventis Laboratoire|NEW THERAPEUTIC APPLICATION OF 1,6-DIMETHYL-8BETA- HYDROXYMETHYL-10ALPHA-METHOXYERGOLINE|
    AU2002258525A1|2001-03-13|2002-09-24|Sierra Sciences, Inc.|Telomerase expression repressor proteins and methods of using the same|
    EP3202790A1|2001-03-15|2017-08-09|Precision Biologics, Inc.|Monoclonal antibody therapy for pancreas cancer|
    WO2003005031A1|2001-07-02|2003-01-16|Sekisui Chemical Co., Ltd.|Carrier particle latex for assay reagent and assay reagent|
    CA2478458A1|2004-08-20|2006-02-20|Michael Panzara|Treatment of pediatric multiple sclerosis|
    ES2633105T3|2010-04-16|2017-09-19|Biogen Ma Inc.|Antibodies against VLA-4|
    BR112012031483B1|2010-06-11|2020-01-07|Basf Se|USES OF THERMOPLASTIC MOLDING COMPOSITIONS AND LASER TRANSPARENT MOLDS, PROCESS TO PRODUCE WELDED MOLDS, AND, WELDED MOLD|
    US8889768B2|2010-06-11|2014-11-18|Basf Se|Laser-transparent PBT with organic additives|
    CN105560244B|2014-10-10|2019-01-11|上海交通大学|A kind of inhibitors of gamma-secretase and its application|
    RU2730668C2|2014-11-19|2020-08-24|Аксон Ньюросайенс Се|Humanised tau antibodies in alzheimer disease|
    WO2017217406A1|2016-06-14|2017-12-21|デンカ株式会社|Membrane carrier for liquid sample test kit, liquid sample test kit, and method for producing liquid sample test kit|
    CN110337589A|2017-03-28|2019-10-15|电化株式会社|Membrane carrier and the liquor sample detection kit and its manufacturing method for using it|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    HU862690A|HU196394B|1986-06-27|1986-06-27|Process for preparing 2-halogenated ergoline derivatives|LV930674A| LV5508A3|1986-06-27|1993-06-28|2-Brom-alpha-ergocriptine or the acquisition of its aditive islands|
    [返回顶部]